Alves, InêsVicente, Manuel MachadoGaifem, JoanaFernandes, ÂngelaDias, Ana MendesRodrigues, Cláudia SousaOliveira, José CarlosSeixas, NairMalheiro, LuisAbreu, MiguelSarmento e Castro, RuiPinho, Salomé Soares2023-10-172023-10-172021Alves I, Vicente MM, Gaifem J, et al. SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis. J Immunol. 2021;207(6):1591-1598. doi:10.4049/jimmunol.21001310022-17671550-6606http://hdl.handle.net/10400.16/2813COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target.engjournal article10.4049/jimmunol.2100131